CAREDX INC (CDNA) Stock Fundamental Analysis
USA - NASDAQ:CDNA - US14167L1035 - Common Stock
14.67 USD
-1.86 (-11.25%)
We assign a fundamental rating of 6 out of 10 to CDNA. CDNA was compared to 534 industry peers in the Biotechnology industry. While CDNA has a great health rating, its profitability is only average at the moment. CDNA is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year CDNA was profitable.
CDNA had a positive operating cash flow in the past year.
CDNA had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CDNA reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of 11.63%, CDNA belongs to the best of the industry, outperforming 94.38% of the companies in the same industry.
The Return On Equity of CDNA (15.79%) is better than 94.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.63% | ||
| ROE | 15.79% | ||
| ROIC | N/A |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 15.16%, CDNA belongs to the best of the industry, outperforming 93.45% of the companies in the same industry.
CDNA has a better Gross Margin (66.90%) than 80.52% of its industry peers.
CDNA's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 15.16% | ||
| GM | 66.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
2. Health
2.1 Basic Checks
CDNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CDNA has more shares outstanding
The number of shares outstanding for CDNA has been increased compared to 5 years ago.
CDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CDNA has an Altman-Z score of 3.31. This indicates that CDNA is financially healthy and has little risk of bankruptcy at the moment.
CDNA has a Altman-Z score of 3.31. This is in the better half of the industry: CDNA outperforms 70.79% of its industry peers.
CDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.31 |
ROIC/WACCN/A
WACC8.74%
2.3 Liquidity
A Current Ratio of 3.30 indicates that CDNA has no problem at all paying its short term obligations.
CDNA has a worse Current ratio (3.30) than 61.42% of its industry peers.
CDNA has a Quick Ratio of 3.00. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
CDNA has a Quick ratio of 3.00. This is in the lower half of the industry: CDNA underperforms 61.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.3 | ||
| Quick Ratio | 3 |
3. Growth
3.1 Past
CDNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 242.11%, which is quite impressive.
The Earnings Per Share has been growing by 37.47% on average over the past years. This is a very strong growth
Looking at the last year, CDNA shows a quite strong growth in Revenue. The Revenue has grown by 19.07% in the last year.
CDNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.30% yearly.
EPS 1Y (TTM)242.11%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%100%
Revenue 1Y (TTM)19.07%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%20.72%
3.2 Future
The Earnings Per Share is expected to grow by 38.18% on average over the next years. This is a very strong growth
Based on estimates for the next years, CDNA will show a quite strong growth in Revenue. The Revenue will grow by 12.93% on average per year.
EPS Next Y1.06%
EPS Next 2Y22.93%
EPS Next 3Y37.54%
EPS Next 5Y38.18%
Revenue Next Year11.33%
Revenue Next 2Y11.62%
Revenue Next 3Y11.66%
Revenue Next 5Y12.93%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 22.57 indicates a rather expensive valuation of CDNA.
Compared to the rest of the industry, the Price/Earnings ratio of CDNA indicates a rather cheap valuation: CDNA is cheaper than 94.01% of the companies listed in the same industry.
CDNA's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.13.
Based on the Price/Forward Earnings ratio of 17.98, the valuation of CDNA can be described as rather expensive.
Based on the Price/Forward Earnings ratio, CDNA is valued cheaply inside the industry as 93.26% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of CDNA to the average of the S&P500 Index (22.35), we can say CDNA is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.57 | ||
| Fwd PE | 17.98 |
4.2 Price Multiples
CDNA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CDNA is cheaper than 91.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 65.74 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as CDNA's earnings are expected to grow with 37.54% in the coming years.
PEG (NY)21.38
PEG (5Y)0.6
EPS Next 2Y22.93%
EPS Next 3Y37.54%
5. Dividend
5.1 Amount
CDNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CDNA (11/6/2025, 1:53:07 PM)
14.67
-1.86 (-11.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.13%
Inst Owner Change-0.02%
Ins Owners2.37%
Ins Owner Change1.51%
Market Cap780.88M
Revenue(TTM)333.79M
Net Income(TTM)51.68M
Analysts80
Price Target22.95 (56.44%)
Short Float %11.79%
Short Ratio4.56
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.98%
Min EPS beat(2)-18.08%
Max EPS beat(2)36.04%
EPS beat(4)3
Avg EPS beat(4)331.94%
Min EPS beat(4)-18.08%
Max EPS beat(4)1272.55%
EPS beat(8)7
Avg EPS beat(8)222.06%
EPS beat(12)11
Avg EPS beat(12)158.17%
EPS beat(16)12
Avg EPS beat(16)125.68%
Revenue beat(2)0
Avg Revenue beat(2)-3.92%
Min Revenue beat(2)-6.22%
Max Revenue beat(2)-1.61%
Revenue beat(4)2
Avg Revenue beat(4)-1.5%
Min Revenue beat(4)-6.22%
Max Revenue beat(4)0.91%
Revenue beat(8)6
Avg Revenue beat(8)8.02%
Revenue beat(12)7
Avg Revenue beat(12)5.22%
Revenue beat(16)8
Avg Revenue beat(16)3.59%
PT rev (1m)0%
PT rev (3m)-23.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.71%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.57 | ||
| Fwd PE | 17.98 | ||
| P/S | 2.29 | ||
| P/FCF | 65.74 | ||
| P/OCF | 44.06 | ||
| P/B | 2.39 | ||
| P/tB | 3.11 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.65
EY4.43%
EPS(NY)0.82
Fwd EY5.56%
FCF(TTM)0.22
FCFY1.52%
OCF(TTM)0.33
OCFY2.27%
SpS6.4
BVpS6.15
TBVpS4.72
PEG (NY)21.38
PEG (5Y)0.6
Graham Number9.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.63% | ||
| ROE | 15.79% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 15.16% | ||
| GM | 66.9% | ||
| FCFM | 3.49% |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
F-Score7
Asset Turnover0.77
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 41.29% | ||
| Cap/Sales | 1.71% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 22.98% | ||
| Current Ratio | 3.3 | ||
| Quick Ratio | 3 | ||
| Altman-Z | 3.31 |
F-Score7
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)106.55%
Cap/Depr(5y)139.53%
Cap/Sales(3y)4.27%
Cap/Sales(5y)5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.11%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%100%
EPS Next Y1.06%
EPS Next 2Y22.93%
EPS Next 3Y37.54%
EPS Next 5Y38.18%
Revenue 1Y (TTM)19.07%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%20.72%
Revenue Next Year11.33%
Revenue Next 2Y11.62%
Revenue Next 3Y11.66%
Revenue Next 5Y12.93%
EBIT growth 1Y35.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year115.46%
EBIT Next 3Y72.56%
EBIT Next 5YN/A
FCF growth 1Y185.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6229.29%
OCF growth 3YN/A
OCF growth 5YN/A
CAREDX INC / CDNA FAQ
What is the ChartMill fundamental rating of CAREDX INC (CDNA) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CDNA.
Can you provide the valuation status for CAREDX INC?
ChartMill assigns a valuation rating of 5 / 10 to CAREDX INC (CDNA). This can be considered as Fairly Valued.
What is the profitability of CDNA stock?
CAREDX INC (CDNA) has a profitability rating of 4 / 10.
What is the valuation of CAREDX INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CAREDX INC (CDNA) is 22.57 and the Price/Book (PB) ratio is 2.39.